Previous 10 | Next 10 |
EDWARDS LIFESCIENCES ANNOUNCES $750 MILLION ACCELERATED SHARE REPURCHASE PR Newswire IRVINE, Calif. , Nov. 1, 2022 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today announced that it has executed an accelerated share repurchase agreement ("ASR") to re...
Summary Edwards Lifesciences has seen shares cut nearly in half from the highs of last year. This is mostly in response to higher interest rates and an overreaction seen towards the upside last year. Current multiples remain demanding, but underlying strength remains solid. ...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify . For further details see: Wall Street Breakfast: What Moved Markets
Stocks rallied on Friday, boosted by a strong earnings report from Apple. All the major averages rose more than 2%, with the Dow climbing more than 800 points to secure its sixth straight day of gains. While Apple gave a lift to the overall market, Amazon ( AMZN ) created a signific...
Summary The Health Care sector continues to generate alpha in 2022, but not all of its holdings are a source of relative safety. Edwards Lifesciences reported a poor Q3 and slashed guidance. Traders reacted harshly to the EPS miss. The stock still looks on the pricey side but ...
Shares of medical device maker Edwards Lifesciences (NYSE: EW) fell 16.6% through 11:45 a.m. ET on Friday even though the company missed analyst targets for third-quarter earnings last night by only the slimmest of margins. Analysts had forecast that Edwards would show earni...
Edwards Lifesciences Corp (EW) Q3 2022 Earnings Conference Call October 27, 2022, 17:00 ET Company Participants Mark Wilterding - VP, IR Michael Mussallem - Chairman & CEO Scott Ullem - Corporate VP & CFO Bernard Zovighian - Corporate VP, Transcathete...
Edwards Lifesciences ( NYSE: EW ) is down 11% in after-hours trading after the company's Q3 2022 top and bottom line results missed and its full-year adjusted EPS guidance range was amended to below the consensus estimate. Edwards ( EW ) now projects 2022 adjus...
Edwards Lifesciences press release ( NYSE: EW ): Q3 Non-GAAP EPS of $0.61 misses by $0.01 . Revenue of $1.32B (+0.8% Y/Y) misses by $10M . Q3 TAVR sales grew 1%; constant currency sales grew 6% Outlook: 2022 adjusted EPS guidance revised to the range of...
EDWARDS LIFESCIENCES REPORTS THIRD QUARTER RESULTS PR Newswire IRVINE, Calif. , Oct. 27, 2022 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2022. Third Quarter...
News, Short Squeeze, Breakout and More Instantly...
Edwards Lifesciences Corporation Company Name:
EW Stock Symbol:
NYSE Market:
Edwards Lifesciences Corporation Website:
Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended June 30, 2024 after the market closes on Wednesday, July 24, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877)...
Edwards Lifesciences (NYSE: EW) today announced it has exercised its option to acquire Innovalve Bio Medical Ltd., an early-stage transcatheter mitral valve replacement (TMVR) company, following its initial investment in 2017. Since that time, Innovalve has demonstrated progress in its program wi...
2024-07-08 19:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...